RayKnowChina Research Map
Shortlist

BeijingPeking University Health Science Center

Peking University People's Hospital

北京大学人民医院

Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Peking University People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌2 papers led
  2. Hepatocellular carcinoma肝细胞癌24 papers led1 open trial led
  3. Stomach cancer胃癌21 papers led3 open trials led
  4. Retinoblastoma视网膜母细胞瘤0 papers led
  5. Chordoma脊索瘤6 papers led
  6. Osteosarcoma骨肉瘤42 papers led2 open trials led
  7. Gastrointestinal stromal tumour胃肠道间质瘤8 papers led2 open trials led
  8. Ewing sarcoma尤文肉瘤7 papers led2 open trials led
  9. Multiple myeloma多发性骨髓瘤19 papers led5 open trials led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病19 papers led4 open trials led
  11. Aplastic anaemia再生障碍性贫血29 papers led3 open trials led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症7 papers led1 open trial led
  13. Haemophilia A血友病 A0 papers led1 open trial led
  14. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜4 papers led2 open trials led
  15. Fanconi anaemia范可尼贫血2 papers led
  16. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led1 open trial led
  17. IgG4-related diseaseIgG4相关性疾病12 papers led1 open trial led
  18. Myasthenia gravis重症肌无力3 papers led
  19. Takayasu arteritis大动脉炎1 paper led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  21. Behçet disease白塞病5 papers led1 open trial led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Gaucher disease戈谢病0 papers led
  24. Osteogenesis imperfecta成骨不全症2 papers led
  25. Primary biliary cholangitis原发性胆汁性胆管炎7 papers led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  27. Congenital diaphragmatic hernia先天性膈疝0 papers led
  28. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Neuroblastoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 2 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapySurgery
Departments in papersGastroenterology / hepatology
Papers it led2
  1. Protocol to establish patient-derived xenograft and organoid for radiosensitivity of esophageal squamous cell carcinoma.2024STAR protocolsFree full text
  2. The negative association between skeletal muscle and fat mass wasting caused by oesophagectomy in patients with oesophageal squamous cell carcinoma.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Chinese-language papers (not in the count)1
  1. [Feasibility of appropriately extending the surgical interval after neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
More papers found outside PubMed (not counted)8
  1. Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.2025Journal of Clinical Oncologyarticle
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  7. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 24 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
24
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 5520232024: 6620242025: 662025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  2. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led24
  1. Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.2025BMC medicineFree full text
  2. Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma.2025Current medicinal chemistry
  3. Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  4. Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.2025Frontiers in immunologyFree full text
  5. Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.2025The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chiFree full text
  6. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  7. Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.2024Abdominal radiology (New York)
  8. Clinical potential of serum prostaglandin A2 as a novel diagnostic biomarker for hepatocellular cancer.2024Clinica chimica acta; international journal of clinical chemistry
  9. All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines.2024International journal of molecular sciencesFree full text
  10. Methodological challenges in studying immune-suppressive neutrophils in HCC models.2024Journal of hepatology
  11. For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?2024Journal of hepatology
  12. Augmentation of hepatocellular carcinoma malignancy by annexin A5 through modulation of invasion and angiogenesis.2024Scandinavian journal of gastroenterology
  13. NDRG1 facilitates self-renewal of liver cancer stem cells by preventing EpCAM ubiquitination.2023British journal of cancerFree full text
  14. A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection.2023Cancer medicineFree full text
  15. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.2023Cancer medicineFree full text
  16. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.2023Frontiers in immunologyFree full text
  17. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.2023Journal for immunotherapy of cancerFree full text
  18. Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  19. Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.2022Frontiers in immunologyFree full text
  20. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.2022VirusesFree full text
  21. Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease.2021BiomoleculesFree full text
  22. Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer.2021Frontiers in endocrinologyFree full text
  23. Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  24. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.2021The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
Chinese-language papers (not in the count)2
  1. [Exploring the reasons for liver cancer occurrence still after long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Lead sponsorN/AStart 2025-06
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  3. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  4. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 4420232024: 3320242025: 552025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07857668

    Age 20 years to 80 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06748690

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  3. Not yet recruiting
    Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07018063

    Age 16 years to 45 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  4. Recruiting
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07714980

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai

  5. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led21
  1. Endoscopic semi-blunt dissection technique is safe and effective for treating gastric submucosal tumors from the muscularis propria.2025BMC gastroenterologyFree full text
  2. Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy.2025Cancer treatment reviews
  3. CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.2025European radiology
  4. CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors.2025Frontiers in immunologyFree full text
  5. Extramural venous invasion in gastric cancer: 9.4T magnetic resonance imaging assessment and circular RNA functional analysis.2025World journal of gastroenterologyFree full text
  6. Sintilimab and Cardiovascular Toxicity.2024JAMA
  7. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.2024Journal of translational medicineFree full text
  8. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer.2024Journal of translational medicineFree full text
  9. Safety and efficacy of vagus nerve-preserving distal gastrectomy for early gastric cancer: A systematic review and meta-analysis.2023Asian journal of surgery
  10. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.2023European radiologyRCT
  11. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.2023Journal of translational medicineFree full text
  12. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer.2023TheranosticsFree full text
  13. Pathological diagnosis, differential diagnosis and origin investigation of easily misdiagnosed adult gastric duplication cysts.2022Histology and histopathology
  14. Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review.2022International journal of surgery (London, England)
  15. Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1.2022World journal of gastroenterologyFree full text
  16. Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.2022World journal of surgical oncologyFree full text
  17. Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer.2021Abdominal radiology (New York)
  18. A signature of 24 aging‑related gene pairs predict overall survival in gastric cancer.2021Biomedical engineering onlineFree full text
  19. CT-detected extramural venous invasion-related gene signature for the overall survival prediction in patients with gastric cancer.2021Cancer medicineFree full text
  20. Diagnosis of gastric lesions through a deep convolutional neural network.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  21. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
Chinese-language papers (not in the count)5
  1. [Research progress on peritoneal metastasis of gastric cancer in the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].2023Zhonghua yi xue za zhi
  3. [Updates on the molecular classification of gastric cancer].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Research progress of single-incision laparoscopic radical gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status11
  1. LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)RecruitingNCT07857668Lead sponsorStart 2026-08
  2. MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMTRecruitingNCT06748690Lead sponsorN/AStart 2024-01
  3. Effects of HIPEC on Postoperative Bowel Motility and ComplicationsActive, not recruitingNCT07353177Lead sponsorStart 2025-04
  4. Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Lead (inferred)Phase 2Start 2025-10
  5. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)RecruitingNCT07714980Study siteN/AStart 2026-07
  6. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  7. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  8. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  9. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  10. Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Study sitePhase 1Start 2019-03
  11. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)3
  1. [Evaluation the risk of optic nerve invasion associated with optic nerve obscuration in advanced retinoblastoma].2020[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [Promoting regulated gene diagnosis for retinoblastoma in clinical work].2019[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  3. [Application of gene capture technology on mutation screening of RB1 gene in retinoblastoma patients].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 6 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 5.7%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 222025

11 hospitals in Beijing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led6
  1. CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.2025Scientific reports
  2. Multi-omics analysis unveils the role of inflammatory cancer-associated fibroblasts in chordoma progression.2025The Journal of pathology
  3. Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects.2024Neuro-oncology
  4. Letter to the Editor Regarding "Hypoxia-inducible Factor-1α (HIF-1α) as a Factor to Predict Prognosis of Spinal Chordoma" by He and Liu.2024Spine
  5. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.2023Frontiers in immunology
  6. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.2023Journal for immunotherapy of cancer
Chinese-language papers (not in the count)1
  1. [Analysis of influencing factors of recurrence after en bloc spondylectomy of spinal tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
Earlier papers (2016–2020)6
  1. Epidemiological characteristics of 1385 primary sacral tumors in one institution in China.2020World journal of surgical oncology
  2. Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.2019European radiology
  3. A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.2019Journal of magnetic resonance imaging : JMRI
  4. Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging.2019The British journal of radiology
  5. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.2018Cell death & disease
  6. One-step reconstruction with a 3D-printed, custom-made prosthesis after total en bloc sacrectomy: a technical note.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
All its trials on ClinicalTrials.gov, any status1
  1. Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic ChordomaStatus unknownNCT04042597Lead sponsorPhase 2Start 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 42 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
42
2021–2025
Trials led
20
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 101020212022: 8820222023: 101020232024: 4420242025: 992025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07479732

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06714383

    Age 14 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  3. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led42
  1. Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.2026Journal of imaging informatics in medicine
  2. T2-weighted magnetic resonance imaging radiogenomic features for the prediction of neoadjuvant chemotherapy response in patients with osteosarcoma.2025Acta radiologica (Stockholm, Sweden : 1987)
  3. Sonographic characteristics of local soft tissue recurrence in primary bone tumor and diagnostic efficacy versus MRI.2025BMC cancer
  4. Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.2025Cell communication and signaling : CCS
  5. Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation.2025Frontiers in immunology
  6. End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.2025Journal of imaging informatics in medicine
  7. Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets.2025Nano letters
  8. Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.2025Nature communicationsRCT
  9. CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.2025Scientific reports
  10. Magnetic resonance imaging assessment of epiphyseal invasion in paediatric osteosarcoma.2025Skeletal radiology
  11. Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  12. Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma.2024Cancer letters
  13. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.2024Diagnostic pathology
  14. Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.2024Oncogene
  15. The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.2023Autophagy
  16. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).2023BMC cancer
  17. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.2023BMC medical imaging
  18. Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma.2023BMC medical imaging
  19. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  20. Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  21. Intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging for neoadjuvant chemotherapy response evaluation in patients with osteosarcoma.2023European journal of radiology
  22. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.2023Orthopaedic surgery
  23. Outcomes of Semiknee Replacement in Skeletally Immature Bone Sarcoma Patients.2023The journal of knee surgery
  24. Outcomes of Fixed-Hinged Knee Prosthesis for Distal Femoral Osteosarcoma in Skeletally Immature Patients: First Results.2023The journal of knee surgery
  25. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.2022Annals of nuclear medicine
  26. Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.2022BMC cancer
  27. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.2022Cancer letters
  28. circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p.2022Cancer science
  29. Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis.2022European journal of cancer care
  30. Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.2022Frontiers in immunology
  31. How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?2022International orthopaedics
  32. Analysis of mechanical complications for patients with extremity sarcoma after biological reconstruction.2022Orthopaedics & traumatology, surgery & research : OTSR
  33. Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.2021Aging
  34. Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment.2021Angewandte Chemie (International ed. in English)
  35. The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.2021Annals of the New York Academy of Sciences
  36. Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China.2021BMC cancer
  37. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.2021Cancer letters
  38. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.2021Cellular oncology (Dordrecht, Netherlands)
  39. RNA-dependent protein kinase is required for interferon-γ-induced autophagy in MG63 osteosarcoma cells.2021Gene
  40. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).2021Medicine
  41. Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases.2021The Journal of bone and joint surgery. American volume
  42. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.2021The oncologist
Chinese-language papers (not in the count)2
  1. [Analysis of influencing factors of recurrence after en bloc spondylectomy of spinal tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Pulmonary embolism secondary to osteosarcoma: a case report and literature review].2021Zhonghua xin xue guan bing za zhi
Earlier papers (2016–2020)31
  1. Multiple primary tumors: a case report and review of the literature.2020BMC musculoskeletal disorders
  2. Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.2020BioMed research international
  3. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B.2020Cancer letters
  4. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.2020Cancer letters
  5. Lateral malleolus en bloc resection for the distal fibula osteosarcoma based on a new classification and proposed reconstruction choice: Analysis of 6 cases prognosis and literature review.2020Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  6. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.2020International journal of clinical oncology
  7. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.2020Journal for immunotherapy of cancer
  8. Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.2020Journal of cellular and molecular medicine
  9. Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.2020Journal of clinical laboratory analysis
  10. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.2020Journal of nanobiotechnology
  11. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.2020Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  12. Novel "double-strut" fibula ankle arthrodesis for large tumor-related bone defect of distal tibia.2019BMC musculoskeletal disorders
  13. [Rasfonin inhibits proliferation and migration of osteosarcoma 143B cells].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  14. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis.2019Cancer letters
  15. Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.2019Cell death & disease
  16. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.2019The oncologist
  17. [Effectiveness of free vascularized fibular graft for bone defect after resection of lower limb malignant tumor].2019Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  18. Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?2018BMC cancer
  19. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.2018Biochemical and biophysical research communications
  20. Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases.2018Cancer medicine
  21. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?2018Clinical orthopaedics and related research
  22. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.2018International journal of oncology
  23. Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.2018Journal of experimental & clinical cancer research : CR
  24. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.2018Journal of hematology & oncology
  25. Rectus femoris branch: An alternative blood supply for a distally based anterolateral thigh flap.2018Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  26. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.2018Scientific reports
  27. Surgical treatment of primary malignant tumours of the distal tibia: clinical outcome and reconstructive strategies.2018The bone & joint journal
  28. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.2017Cell death & disease
  29. Anti-angiogenesis target therapy for advanced osteosarcoma (Review).2017Oncology reports
  30. Surgical Treatment of Primary Osteosarcoma of the Sacrum: A Case Series of 26 Patients.2017Spine
  31. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.2016Journal of experimental & clinical cancer research : CR
All its trials on ClinicalTrials.gov, any status23
  1. Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaRecruitingNCT07479732Lead sponsorPhase 1/Phase 2Start 2026-03
  2. Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingNCT06714383Lead sponsorPhase 2Start 2024-11
  3. the Exploration of MTAP Deletion in Osteosarcoma by ImmunohistochemistryActive, not recruitingNCT07593573Lead sponsorStart 2025-12
  4. B7-H3 NIR Imaging for Osteosarcoma SurgeryRecruitingNCT06778603Lead sponsorPhase 1/Phase 2Start 2024-01
  5. Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506Lead sponsorStart 2024-09
  6. Soluble B7-H3 as a Biomarker for OsteosarcomaStatus unknownNCT05942456Lead sponsorStart 2023-06
  7. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)CompletedNCT05277480Lead sponsorPhase 2Start 2022-03
  8. Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory OsteosarcomaSuspendedNCT04824352Lead sponsorPhase 2Start 2021-04
  9. Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory OsteosarcomaCompletedNCT04690231Lead sponsorN/AStart 2020-12
  10. Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Lead sponsorPhase 2Start 2020-05
  11. Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective StudyCompletedNCT04546243Lead sponsorStart 2020-01
  12. Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity OsteosarcomaCompletedNCT03909776Lead sponsorN/AStart 2019-01
  13. Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OSCompletedNCT03997747Lead sponsorStart 2019-08
  14. Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and CamrelizumabStatus unknownNCT03919539Lead sponsorStart 2019-12
  15. Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawnNCT04044378Lead sponsorPhase 1/Phase 2Start 2019-08
  16. Apatinib Plus Anti-PD1 Therapy for Advanced OsteosarcomaCompletedNCT03359018Lead sponsorPhase 2Start 2018-01
  17. PD-L1 Expression in Advanced OsteosarcomaStatus unknownNCT03582527Lead sponsorStart 2018-06
  18. Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and SacrumStatus unknownNCT03360760Lead sponsorN/AStart 2018-08
  19. Epigenetic Biomarker for OsteosarcomaStatus unknownNCT03336554Lead sponsorStart 2017-09
  20. Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal TherapyCompletedNCT02711007Lead (inferred)Phase 2/Phase 3Start 2016-03
  21. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  22. Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedNCT06935409Study sitePhase 3Start 2025-04
  23. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Study sitePhase 1/Phase 2Start 2023-01

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 8 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.5%.

Papers led
8
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 3320232024: 0020242025: 332025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06748690

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT05408897

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicine
Papers it led8
  1. Disparities in management guidelines for gastrointestinal stromal tumors: A comparison of recommendations from the Chinese Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society for Medical Oncology.2025Cancer
  2. Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition).2025Cancer
  3. CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.2025European radiology
  4. Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.2023Annals of diagnostic pathology
  5. Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.2023European radiologyRCT
  7. Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.2021BMC gastroenterologyRCT
  8. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
Chinese-language papers (not in the count)2
  1. [From following to surpassing: insight into GIST treatment development in China].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].2023Zhonghua yi xue za zhi
Earlier papers (2016–2020)6
  1. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: A systematic review and meta-analysis.2020European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map.2020World journal of gastroenterology
  3. [Evidence-based standardized diagnosis and treatment of small gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Minimally invasive surgery for gastrointestinal stromal tumors--pursuing the trivial, or striving for perfection].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1.2018Chinese medical journal
  6. The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors.2017BMC gastroenterology
All its trials on ClinicalTrials.gov, any status4
  1. MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMTRecruitingNCT06748690Lead sponsorN/AStart 2024-01
  2. Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDRecruitingNCT05408897Lead sponsorStart 2022-01
  3. Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionEnrolling by invitationNCT07550582Lead sponsorPhase 2Start 2026-04
  4. A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid BiopsySuspendedNCT05867901Lead sponsorStart 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 7 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 4.3%.

Papers led
7
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 1120242025: 112025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07725783

    Age 10 years to 60 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06340204

    Age 8 years to 40 years (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Jinan

  3. Recruiting
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06926283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Papers it led7
  1. Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.2025Cell communication and signaling : CCS
  2. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.2024Diagnostic pathology
  3. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.2023BMC medical imaging
  4. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  5. Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.2022BMC cancer
  6. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).2021Medicine
  7. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.2021The oncologist
Earlier papers (2016–2020)2
  1. Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.2020BioMed research international
  2. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.2016Journal of experimental & clinical cancer research : CR
All its trials on ClinicalTrials.gov, any status8
  1. Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing SarcomaRecruitingNCT07725783Lead sponsorStart 2025-09
  2. Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Lead sponsorPhase 1Start 2024-03
  3. Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing SarcomaNot yet recruitingNCT07620431Lead sponsorStart 2026-06
  4. Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506Lead sponsorStart 2024-09
  5. Irinotecan and Temozolomide for Ewing SarcomaStatus unknownNCT03359005Lead sponsorPhase 2Start 2018-02
  6. Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Lead sponsorPhase 1/Phase 2Start 2018-01
  7. A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsRecruitingNCT06926283Study sitePhase 1Start 2025-05
  8. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
19
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 5520232024: 1120242025: 442025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    KPD Consolidation After ASCT in NDMM Patients
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06879379

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai

  2. Recruiting
    Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07296627

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  3. Recruiting
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06697483

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin

  4. Not yet recruiting
    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07320326

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  5. Not yet recruiting
    A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06369935

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  6. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  7. Recruiting
    A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07652281

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  8. Recruiting
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT06514508

    Age 18 years to 78 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  10. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  11. Not yet recruiting
    A Open-Label Phase in Participants With Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07764861

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskBispecific & antibody drugs
Departments in papersNephrologyRadiology / nuclear medicineENT / head & neck surgeryPathology / laboratory medicine
Papers it led19
  1. Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.2026Acta haematologica
  2. Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.2026Acta haematologica
  3. Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: 2026Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  4. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.2025Annals of hematology
  5. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.2025BMC cancerFree full text
  6. The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050.2025Cancer letters
  7. Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.2025Cancer medicineFree full text
  8. Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes.2024Nature communicationsFree full text
  9. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.2023Annals of hematologyRCTFree full text
  10. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.2023BMC cancerFree full text
  11. Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?2023Chinese medical journalFree full text
  12. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.2023Clinical lymphoma, myeloma & leukemiaRCT
  13. Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.2023Renal failureFree full text
  14. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.2022BMC cancerFree full text
  15. Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma.2022BioMed research internationalFree full text
  16. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?2022Clinical lymphoma, myeloma & leukemia
  17. Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.2022International journal of biological sciencesFree full text
  18. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.2021Clinical lymphoma, myeloma & leukemiaRCT
  19. Extramedullary plasmacytoma of the nasal inferior turbinate: a case report.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)13
  1. [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. [Guidelines for the diagnosis and management of multiple myeloma: 2024 updates].2024Zhonghua nei ke za zhi
  3. [Treatment options for multiple myeloma with renal injury].2024Zhonghua nei ke za zhi
  4. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].2024Zhonghua yi xue za zhi
  5. [Current status and challenges of immunotherapy for multiple myeloma].2024Zhonghua yi xue za zhi
  6. [A single-center retrospective analysis of 100 consecutive cases treated with lenalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma].2022Zhonghua nei ke za zhi
  7. [A message to the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)-a step further, a level higher].2022Zhonghua nei ke za zhi
  8. [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [Analysis of clinical features of multiple myeloma with t(8;14)(q24;q32)].2022Zhonghua yi xue za zhi
  10. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  11. [Progress in the treatment of multiple myeloma with daratumumab].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  12. [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  13. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status26
  1. ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By ElranatamabNot yet recruitingNCT07320326Lead sponsorStart 2025-12
  2. Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07296627Lead sponsorStart 2025-07
  3. KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Lead sponsorPhase 2/Phase 3Start 2025-03
  4. Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Lead sponsorN/AStart 2024-12
  5. A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Not yet recruitingNCT06369935Lead sponsorStart 2024-06
  6. Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06924424Lead sponsorN/AStart 2025-03
  7. Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS InvolvementStatus unknownNCT05478993Lead sponsorPhase 2Start 2022-10
  8. Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MMStatus unknownNCT05438394Lead sponsorPhase 1Start 2022-10
  9. A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaStatus unknownNCT01868828Lead sponsorPhase 4Start 2013-05
  10. A Clinical Study of SHR-5421 in Patients With Multiple MyelomaRecruitingNCT07652281Study sitePhase 1Start 2026-07
  11. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  12. A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingNCT07764861Study sitePhase 2Start 2026-08
  13. Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsRecruitingNCT06514508Study sitePhase 3Start 2025-12
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  15. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  16. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  17. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  18. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  19. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  20. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  21. Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCompletedNCT06425276Study sitePhase 4Start 2020-07
  22. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  23. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  24. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Study siteStart 2016-07
  25. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11
  26. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Study sitePhase 3Start 2008-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 19 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 8.4%.

Papers led
19
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 5520232024: 8820242025: 222025

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07441291

    Age 3 years to 79 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06581081

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  3. Recruiting
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06880913

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  4. Not yet recruiting
    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07919470

    Age 14 years to 65 years (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang

  5. Recruiting
    Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT07244406

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  6. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  7. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenPhiladelphia chromosome & geneticsCAR-T & cell therapy
Departments in papersPediatrics
Papers it led19
  1. Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.2025Frontiers in immunologyFree full text
  2. Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.2025Leukemia & lymphoma
  3. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.2024Cancer letters
  4. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.2024Cancer research and treatmentFree full text
  5. Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.2024Clinical and experimental medicineFree full text
  6. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.2024Clinical lymphoma, myeloma & leukemia
  7. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.2024Hematological oncology
  8. CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.2024Journal of pediatric hematology/oncology
  9. Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.2024Journal of translational medicineFree full text
  10. Long-Term Survival and Immune Reconstitution of Donor-Derived Chimeric Antigen Receptor T-Cell Therapy for Childhood Molecular Relapse of B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.2024Pediatric hematology and oncology
  11. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.2023Acta haematologica
  12. CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.2023Biomolecules & biomedicineFree full text
  13. Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.2023Chinese medical journalFree full text
  14. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.2023Hematological oncology
  15. The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.2023Leukemia & lymphoma
  16. Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.2022Leukemia
  17. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.2022Pediatric hematology and oncology
  18. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.2021Clinical lymphoma, myeloma & leukemia
  19. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.2021Leukemia
Chinese-language papers (not in the count)1
  1. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with TCF3/PBX1+ B-cell Acute Lymphoblastic Leukemia].2023Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCTNot yet recruitingNCT07919470Lead sponsorN/AStart 2026-11
  2. CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTRecruitingNCT07441291Lead sponsorPhase 3Start 2025-11
  3. Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALLRecruitingNCT06880913Lead sponsorPhase 1/Phase 2Start 2024-11
  4. Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06581081Lead sponsorN/AStart 2024-10
  5. Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLRecruitingNCT07244406Study sitePhase 2Start 2025-01
  6. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.RecruitingNCT06927466Study sitePhase 1Start 2024-09
  7. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaRecruitingNCT06450067Study siteStart 2024-06
  8. Safety and Efficacy Evaluation of IM19 CAR-T CellsStatus unknownNCT03142646Study sitePhase 1/Phase 2Start 2016-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 29 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 7.0%.

Papers led
29
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 101020222023: 5520232024: 3320242025: 772025

6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07586735

    Age 40 years to 60 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07629947

    Age 18 years to 40 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  3. Recruiting
    A Prediction Model in Pregnant Women With Aplastic Anemia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07101770

    Age 20 years to 50 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantChildrenInfection & supportive care
Papers it led29
  1. Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.2026Chinese medical journalFree full text
  2. The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.2025Annals of hematologyFree full text
  3. The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.2025Bone marrow transplantation
  4. Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.2025Cancer letters
  5. The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Study From the Chinese 2025Clinical transplantation
  6. Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.2025Cytotherapy
  7. TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia.2025Experimental & molecular medicineFree full text
  8. G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.2025Transplantation and cellular therapy
  9. Ovarian tissue cryopreservation after graft failure of allogeneic hematopoietic stem cell transplantation: first report and literature review.2024Frontiers in endocrinologyFree full text
  10. The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry group.2024HaematologicaFree full text
  11. BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.2024Signal transduction and targeted therapyFree full text
  12. Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.2023Annals of hematology
  13. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation.2023Bone marrow transplantation
  14. Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem2023Bone marrow transplantation
  15. Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.2023Frontiers in immunologyFree full text
  16. Repair of dysfunctional bone marrow endothelial cells alleviates aplastic anemia.2023Science China. Life sciences
  17. Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia.2022Annals of hematology
  18. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.2022Bone marrow transplantation
  19. Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.2022British journal of haematology
  20. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation.2022British journal of haematology
  21. A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity.2022Clinical transplantation
  22. The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia.2022Frontiers in immunologyFree full text
  23. Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.2022Haematologica
  24. The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents.2022Pediatric blood & cancer
  25. Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study.2022Science bulletin
  26. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.2022The Lancet. Haematology
  27. Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.2021Bone marrow transplantation
  28. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia.2021Clinical transplantation
  29. Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings.2021Expert review of hematology
Chinese-language papers (not in the count)5
  1. [Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Severe cardiotoxic characteristics associated with allogeneic hematopoietic stem cell transplantation preconditioning in patients with aplastic anemia].2024Zhonghua nei ke za zhi
  3. [Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Safety and survival analysis of haplo-identical hematopoietic stem cell transplantation in patients with severe aplastic anemia who had previous failure to antithymoglobulin treatment].2023Zhonghua nei ke za zhi
  5. [Erythrocytosis after hematopoietic stem cell transplantation: report of 3 cases and literature review].2023Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status5
  1. A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAARecruitingNCT07586735Lead sponsorStart 2026-06
  2. Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic AnemiaRecruitingNCT07629947Lead sponsorN/AStart 2026-06
  3. A Prediction Model in Pregnant Women With Aplastic AnemiaRecruitingNCT07101770Lead sponsorStart 2025-11
  4. The Optimization of Conditioning Regimen for HLA Matched HSCT in SAAStatus unknownNCT06069180Lead sponsorPhase 4Start 2023-11
  5. Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAAStatus unknownNCT03821987Lead sponsorN/AStart 2018-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 7 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.8%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 222025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07905066

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersDiagnosis & prognosisChildren
Departments in papersRheumatology & immunologyPediatrics
Papers it led7
  1. Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.2025Annals of hematologyFree full text
  2. Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.2025Lupus science & medicineFree full text
  3. Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.2024Annals of hematology
  4. COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.2024British journal of hospital medicine (London, England : 2005)
  5. A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.2023Frontiers in immunologyFree full text
  6. Hemophagocytic Lymphohistiocytosis Secondary to Juvenile Myelomonocytic Leukemia: A Case Report and Review of the Literature.2022Journal of pediatric hematology/oncology
  7. Hemophagocytic syndrome and neurological involvement in a case of intravascular large B-cell lymphoma.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)2
  1. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  2. [Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell TransplantationRecruitingNCT07905066Lead sponsorStart 2026-10
  2. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  3. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04
More papers found outside PubMed (not counted)2
  1. Analysis of Acute Leukemia-Associated Hemophagocytic Lymphohistiocytosis in Adults: A Single-Center Experience2025Immunoarticle
  2. Ectopic EBV infection in T cells following allogeneic hematopoietic stem cell transplantation: Clinical outcomes and immunological characterization2025Bloodconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07416526

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Systemic lupus erythematosus with acquired hemophilia A: a case report].2018Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
All its trials on ClinicalTrials.gov, any status2
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Lead sponsorStart 2024-11
  2. A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ARecruitingNCT07416526Study sitePhase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 4 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 6.2%.

Papers led
4
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

  2. Recruiting
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06794008

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 2 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 2.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

3 hospitals in Beijing for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07809724

    Age 18 years to 74 years (registered criteria)

    Led by Peking University People's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum DisorderNot yet recruitingNCT07809724Lead sponsorPhase 2Start 2026-08

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 12 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.9%.

Papers led
12
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 2220232024: 0020242025: 332025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06794008

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesHead, eye socket & salivary glandsDiagnosis & look-alikesTreatment & relapse
Departments in papersRheumatology & immunologyPathology / laboratory medicine
Papers it led12
  1. Primary intraosseous Rosai-Dorfman disease: Clinicopathological features and an assessment of a possible relationship with IgG4-related disease.2025Annals of diagnostic pathology
  2. Clinical characterization of malignant lymphoma mimicking IgG4-related disease.2025Clinical rheumatology
  3. Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.2025Rheumatology (Oxford, England)
  4. Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.2023Clinical and experimental rheumatology
  5. Immune phenotype changes in IgG4-related disease: CD161 + Treg and Foxp3 + Treg.2023Clinical rheumatology
  6. Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.2022Clinical and experimental rheumatology
  7. IL-7 Promotes the Expansion of Circulating CD28- Cytotoxic T Lymphocytes in Patients With IgG4-Related Disease via the JAK Signaling.2022Frontiers in immunologyFree full text
  8. Characteristics of IgG4-related disease complicated with allergic rhinitis or chronic rhinosinusitis: a large cross-sectional cohort study.2022Scientific reportsFree full text
  9. Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.2021Arthritis research & therapyFree full text
  10. Needle biopsy compared with surgical biopsy: pitfalls of small biopsy in histologial diagnosis of IgG4-related disease.2021Arthritis research & therapyFree full text
  11. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.2021Rheumatology (Oxford, England)
  12. Disparities between IgG4-related kidney disease and extrarenal IgG4-related disease in a case-control study based on 450 patients.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [Clinical characteristics of central nervous system involvement in IgG4 related diseases].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status2
  1. BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Lead sponsorPhase 2Start 2024-12
  2. Tofacitinib in the Treatment of IgG4 Related DiseasesCompletedNCT07827469Lead sponsorN/AStart 2023-04
More papers found outside PubMed (not counted)5
  1. POS1249 CIRCULATING GRANZYME K+ CD8+ T CELLS UNDERLYING THE MECHANISMS OF IgG4-RELATED DISEASE2025Annals of the Rheumatic Diseasesconference-abstract
  2. POS0922 DIFFERENTIAL DIAGNOSIS OF FOCAL IMMUNOGLOBULIN G4-RELATED SIALADENITIS AND BENIGN SALIVARY MASSES: THE VALUE OF CONTRAST-ENHANCED ULTRASOUND2023Annals of the Rheumatic Diseasesconference-abstract
  3. Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity2022Rheumatology & autoimmunityarticle
  4. AB0758 CLINICAL PROFILES DIFFER IN IGG4-RELATED DISEASE WITH AND WITHOUT ATOPY: A LARGE CASE-CONTROL STUDY IN CHINA2021Annals of the Rheumatic Diseasesconference-abstract
  5. POS1384 DIFFERENT CLINICAL CHARACTERISTICS OF IGG4-RRD PATIENTS AND NON-IGG4-RRD PATIENTS: A LARGE CHINESE COHORT STUDY2021Annals of the Rheumatic Diseasesconference-abstract

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCrisis & intensive careBiologic & complement drugsAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led1
  1. Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.2025Rheumatology (Oxford, England)
Earlier papers (2016–2020)1
  1. Ultrasound morphological changes in the carotid wall of Takayasu's arteritis: monitor of disease progression.2016International angiology : a journal of the International Union of Angiology
All its trials on ClinicalTrials.gov, any status2
  1. Upadacitinib for Refractory Takayasu ArteritisCompletedNCT07500467Lead (inferred)Start 2024-03
  2. Baricitinib for Refractory Takayasu ArteritisCompletedNCT06662721Lead (inferred)Phase 2Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 5 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
5
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06794008

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  2. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

  3. Recruiting
    AutoInflammatory Disease Alliance Registry (AIDA)
    Phase
    Not given
    Started
    2020-08
    Registry
    NCT05200715

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunologyPathology / laboratory medicine
Papers it led5
  1. Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.2024Clinical and experimental medicine
  2. Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.2023Annals of the rheumatic diseases
  3. Comparison of different onset ages in patients with Behcet's disease.2023Clinical rheumatology
  4. Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.2023Rheumatology (Oxford, England)
  5. Refractory Behçet's disease treated with low-dose interleukin-2: A case report.2022Medicine
Chinese-language papers (not in the count)1
  1. [The distribution of biomarkers for Behcet syndrome and their clinical relevance in real-world studies].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Earlier papers (2016–2020)5
  1. [Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.2018PloS one
  3. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.2017Clinical and experimental rheumatology
  4. [Capsule endoscopy for Behcet's disease-treatment: five cases reports].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  5. Outcomes of surgery for patients with Behcet's disease causing aortic pseudoaneurysm: a shift from open surgery to endovascular repair.2016Clinics (Sao Paulo, Brazil)
All its trials on ClinicalTrials.gov, any status9
  1. BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Lead sponsorPhase 2Start 2024-12
  2. Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.Not yet recruitingNCT07833163Lead sponsorPhase 2Start 2026-09
  3. Ivarmacitinib for Refractory Behcet's SyndromeWithdrawnNCT07634848Lead (inferred)Phase 2Start 2026-06
  4. Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic SyndromeCompletedNCT07582991Lead (inferred)Phase 2Start 2024-03
  5. Upadacitinib for Refractory Behcet's SyndromeCompletedNCT07080346Lead (inferred)Phase 2Start 2024-01
  6. Low-dose IL-2 Treatment on Behcet's DiseaseCompletedNCT04065672Lead (inferred)Phase 2Start 2021-10
  7. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  8. AutoInflammatory Disease Alliance Registry (AIDA)RecruitingNCT05200715Study siteStart 2020-08
  9. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status6
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  4. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  5. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  6. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)CompletedNCT01074944Study sitePhase 3Start 2010-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 2 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

5 hospitals in Beijing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 7 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 0020232024: 1120242025: 222025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led7
  1. Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.2025BMC gastroenterology
  2. Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.2025Scientific reports
  3. The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models.2024BMC gastroenterology
  4. Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.2022Disease markers
  5. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.2022Expert review of gastroenterology & hepatology
  6. Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.2022Medicine
  7. Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.2022Medicine
Earlier papers (2016–2020)1
  1. [Situation analysis of timing of first visit of anti-mitochondrial antibody-positive patients].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Study sitePhase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Beijing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. A Rare Case of Laparoscopic Repair of Simultaneously Occurring Morgagni and Paraesophageal Hernias.2016Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京大学人民医院

Peking University People's Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
a Peking University People's Hospital; China Peking University People's Hospital; PKUPH

Suggest a correctionDownload the data